Immunotherapy

Immunotherapy Side Effects May Be More Common Than Thought

Immunotherapy Side Effects May Be More Common Than Thought

Higher rates of adverse events observed for immune checkpoint inhibitors in real-world settings, compared to clinical trials.

Commission Seeks Standardized Adverse Event Assessments in Hematologic Malignancies

Commission Seeks Standardized Adverse Event Assessments in Hematologic Malignancies

By

A snapshot of an international Commission's report on the issues inherent with adverse event reports of hematologic malingnancies in clinical trials.

CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma

CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma

By

Survival and progression-free survival were better with nivolumab alone or with ipilimumab vs ipilimumab alone for stage III or IV melanoma with known BRAFV600 mutation, according to results of this randomized study.

ASCO, SITC Release Recommendations for Clinical Trial Reporting of Immunotherapy Adverse Events

ASCO, SITC Release Recommendations for Clinical Trial Reporting of Immunotherapy Adverse Events

By

As immunotherapies gain a stronger foothold as a treatment option for cancer, ASCO and SITC convened a panel to develop recommendations to ensure consistent and efficient clinical trial reporting in immuno-oncology.

Prior Bortezomib Lowers Incidence of Lenalidomide-Induced Skin Toxicity in Multiple Myeloma

Prior Bortezomib Lowers Incidence of Lenalidomide-Induced Skin Toxicity in Multiple Myeloma

By

A study presented at ESMO 2018 demonstrated that incidence of skin toxicity in patients with multiple myeloma undergoing lenalidomide therapy was lower in those who received prior bortezomib.

Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer

Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer

Atezolizumab plus nab-paclitaxel prolongs progression-free survival in metastatic disease.

Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC

Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC

By

A retrospective study of patients with NSCLC from 2 cancer centers demonstrates that concurrent use of corticosteroids with PD-1 or PD-L1 inhibitors at baseline decreases progression-free and overall survival for these patients.

Assessment Tool for Immunotherapy Side Effects

Assessment Tool for Immunotherapy Side Effects

By

My patient is receiving immunotherapy. What is the best tool for assessing side effects?

Novel Immunotherapy May Increase Survival in Melanoma Brain Metastases

Novel Immunotherapy May Increase Survival in Melanoma Brain Metastases

Researchers used data from the National Cancer Database to evaluate the overall survival of patients who presented with cutaneous MBM from 2010 to 2015.

FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma

FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma

By

The manufacturer of daratumumab, a CD38-directed antibody for the treatment of multiple myeloma, has submitted a sBLA and a type II variation to the US FDA and European Medicines Agency, respectively, for approval of a split dosing regimen.

Is Radioimmunotherapy a Path Forward for Melanoma?

Is Radioimmunotherapy a Path Forward for Melanoma?

By

Recent research implicates patients' immune cells appear to stimulate radiation abscopal effects, raising the possibility that combining radiotherapy and immunotherapy could yield previously-untapped treatment synergies to improve tumor control.

 Tissue Tumor Mutational Burden Predictive of Response to Immunotherapy 

Tissue Tumor Mutational Burden Predictive of Response to Immunotherapy 

By

Researchers found that tTMB was associated with efficacy across the various study tumor types.

Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma

Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma

By

In an analysis of 11 studies, researchers investigated whether the benefits of carfilzomib for multiple myeloma outweigh the cardiovascular risks. However, the researchers recommend careful monitoring and management of blood pressure and volume status as good clinical practice, regardless.

Drug Classification of Trastuzumab

Drug Classification of Trastuzumab

By

Is trastuzumab classified as an immunotherapy? If so, how does it work?

Navigating the Benefits and Challenges of Immunotherapy

Navigating the Benefits and Challenges of Immunotherapy

By

A review of immunotherapy — what they are, how they work, and what to watch for — was presented at the 2018 ONA Navigation Summit.

Are Ovarian Cancer Stem Cells the Target for Innovative Immunotherapy?

Are Ovarian Cancer Stem Cells the Target for Innovative Immunotherapy?

[OncoTargets and Therapy] In a review of cancer stem cells (CSCs)/ovarian cancer stem cells (OCSCs), researchers discuss the implications of immunotherapy development based on studying cancer evolution by CSCs, and targeting OCSC surface markers to develop CAR-T immunotherapy.

Ado-trastuzumab Emtansine Effective in HER2 Amplified Non-breast, Non-gastric Cancers

Ado-trastuzumab Emtansine Effective in HER2 Amplified Non-breast, Non-gastric Cancers

By

Study results presented at 2018 ASCO Annual Meeting demonstrated effectiveness of ado-trastuzumab emtansine in non-breast non-gastric HER2-amplified cancers.

Durable Response Achieved With Nivolumab in Untreated Melanoma Brain Metastases

Durable Response Achieved With Nivolumab in Untreated Melanoma Brain Metastases

By

In this phase 2 study, researchers randomly assigned 79 patients with immunotherapy-naive melanoma with brain metastases to receive either nivolumab plus ipilimumab or nivolumab alone.

Dabrafenib-Trametinib Combination Approved for Mutation-Positive Thyroid Cancer

Dabrafenib-Trametinib Combination Approved for Mutation-Positive Thyroid Cancer

By

FDA grants approval to immunotherapy combination in the treatment of unresectable and metastatic BRAF V600E mutation-positive anaplastic thyroid cancer (ATC).

Preexisting Rheumatoid Disease Not a Deterrent to Immune Checkpoint Inhibitor Therapy

Preexisting Rheumatoid Disease Not a Deterrent to Immune Checkpoint Inhibitor Therapy

By

Investigators reviewed clinical data from patients with cancer and pre-existing rheumatic disease treated with ipilimumab, nivolumab, or pembrolizumab.

Venetoclax Found Effective in Relapsed/Refractory Chronic Lymphocytic Leukemia

Venetoclax Found Effective in Relapsed/Refractory Chronic Lymphocytic Leukemia

By

A group of Australian researchers report study findings that demonstrate a significant improvement in PFS in patients with relapsed/refractory CLL treated with venetoclax plus rituximab compared with the standard care.

Intratumor Rotavirus Therapy Has Potential to Overcome Immunotherapy Resistance

Intratumor Rotavirus Therapy Has Potential to Overcome Immunotherapy Resistance

In immunocompetent murine models of lymphoma and neuroblastoma, IT rotavirus therapy demonstrated that it can overcome immune checkpoint inhibitor resistance.

Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma

Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma

By

In a post-hoc analysis of the ASPIRE trial results, in which carfilzomib was discontinued due to a lack of long-term safety data, researchers present the safety and efficacy findings of KRd vs Rd for relapsed multiple myeloma at 18 months from randomization.

Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma

Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma

By

Researchers report on finding of a double-blind phase 3 study on the efficacy of adjuvant vemurafenib in patients with resected stage IIC to IIIB melanoma.

Axitinib Plus Pembrolizumab Shows Promise in Treatment-Naïve Advanced RCC

Axitinib Plus Pembrolizumab Shows Promise in Treatment-Naïve Advanced RCC

By

Nonrandomized trial demonstrates tolerability and antitumor activity of a PD-1 checkpoint inhibitor plus a VEGF-TKI in patients with treatment-naïve advanced RCC.

Immunotherapy Tolerable for Cancer Patients With Rheumatologic Disease

Immunotherapy Tolerable for Cancer Patients With Rheumatologic Disease

By

In this retrospective study, researchers sought to determine if cancer patients with rheumatologic disease would be able to tolerate cancer treatment with immune checkpoint inhibitors or if these agents would induce a rheumatologic disease flare.

Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC

Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC

By

Safety and efficacy of atezolizumab with cobimetinib for heavily pretreated metastatic CRC was demonstrated in a phase 1b study that was presented at the 2018 Gastrointestinal Cancers Symposium.

Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib

Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib

By

Results of the double-blind phase 3 CELESTIAL study, presented at the 2018 Gastrointestinal Cancers Symposium, demonstrated efficacy of cabozantinib in patients with HCC who were previously treated with sorafenib.

FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC

FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC

By

Combination therapy with lenvatinib and pembrolizumab is granted Breakthrough Therapy Designation for the treatment of advanced or metastatic renal cell carcinoma (RCC).

FDA Grants Breakthrough Therapy Designation to Ribociclib for HR+/HER2- Breast Cancer

FDA Grants Breakthrough Therapy Designation to Ribociclib for HR+/HER2- Breast Cancer

By

FDA grants Breakthrough Therapy designation for ribociclib as an initial endocrine-based therapy for HR+/HER2- breast cancer in premenopausal or perimenopausal women.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs